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Abstract
Ovarian cancer, a term that encompasses ovarian, fallopian, and peritoneal
cancers, is the leading cause of gynecologic cancer mortality. To improve
patient outcomes, the field is currently focused on defining the mechanisms of
cancer formation and spread, early diagnosis and prevention, and developing
novel therapeutic options. This review summarizes recent advances in these
areas.
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Introduction
Ovarian cancer was first identified in 1959 by Dr Martin Swerd-
low, who described a malignant pelvic mass that surrounded the 
left fallopian tube but did not involve the mucosal epithelium. This 
tumor was thought to develop from tissue with an origin similar to 
that of the ovary, such as the pelvic peritoneum, fallopian tubes, or 
uterus1. Since then, cancers of these tissues have been collectively 
referred to as Müllerian adenocarcinomas to reflect the fact that we 
often do not know exactly which organ these tumors originate from. 
However, for simplicity, we will refer to these tumors by their more 
common name, ovarian cancers. Ovarian cancer is the most lethal 
gynecologic malignancy and is the fifth most common cause of 
cancer death in women2,3.
The majority of women with ovarian cancer are diagnosed with 
advanced-stage disease; only 15% of all cases are diagnosed with 
local disease2,3. Since the 1970s, the five-year survival for all stages 
has improved from 30% to 46%3 as a result of taxane and platinum 
chemotherapies, intraperitoneal (IP) administration of chemother-
apy, and risk-reduction surgeries. However, five-year survival for 
advanced disease, such as stage IIIC, is a mere 39%. Risk factors 
for ovarian cancer include family history, nulliparity, lack of breast 
feeding, and infertility4. In addition, between 5% and 15% of all 
women with ovarian cancer have inherited mutations in DNA repair 
genes such as BRCA1, BRCA2, and genes associated with Lynch 
syndrome4–7. BRCA1, BRCA2, and Lynch mutations increase the 
lifetime risks of ovarian cancer by as much as 60-, 30-, and 13-
fold, respectively5,8. Currently, the field is focused on defining the 
mechanisms of cancer formation and spread, early diagnosis and 
prevention, and developing novel therapeutic options. This review 
highlights some of the newest findings in these areas.
Mechanisms of ovarian cancer formation and spread
Tumor types
The majority of ovarian cancers are of epithelial histology, and 
high-grade serous carcinomas (HGSCs) are the most common, but 
there are other epithelial histologic subtypes, such as clear cell, 
endometrioid, and mucinous4. These can be divided into two major 
subtypes: type I and type II. Type I cancers (clear cell, endome-
trioid, and low-grade serous) grow slowly and seem to develop in 
a step-wise process. For example, low-grade serous tumors arise 
from benign serous cystadenoma or Müllerian inclusion cysts that 
accumulate mutations in pathways such as KRAS and BRAF9. 
Likewise, clear cell and endometrioid carcinomas may originate 
from endometriosis as shown by the finding that the prevalence 
of self-reported endometriosis was higher in women with clear 
cell (20%) and endometrioid (14%) cancers than in those with 
low-grade serous (9.2%) or mucinous (6%) cancers10. Type II 
tumors are characterized by high-grade, rapidly progressive 
disease, and most commonly a serous histology11,12.
Origin of disease
Although ovarian cancers were traditionally thought to originate 
from the surface epithelium of the ovary, there is strong evidence 
that a portion (50–60%) of high-grade serous ovarian tumors arise 
from the fallopian tube, and many pathologists have described 
pre-invasive dysplastic lesions within the distal end of the fallo-
pian tube. These serous tubal intraepithelial carcinoma (STIC) 
lesions11,13–16 often resemble high-grade serous cancer, confirm-
ing that ovarian serous cancer can originate in the fallopian tube. 
However, two recent studies indicate that STIC lesions sometimes 
represent a metastatic site rather than assumptive primary fallopian 
tube cancers17,18. In one study, Eckert et al. implanted HGSC sphe-
roids into the fallopian tube epithelium in mice and showed that this 
fallopian tube growth histologically mimicked STIC lesions17. In 
another study, McDaniel et al. performed targeted next-generation 
sequencing of an incidental STIC lesion and found that it matched 
the associated uterine endometrioid carcinoma, strongly indicating 
that the STIC lesion originated as a micrometastasis from the pri-
mary tumor18. Thus, although certain aspects regarding the origins 
of high-grade serous ovarian cancer are understood, unanswered 
questions continue to challenge the field.
Mutations and pathways
The Cancer Genome Atlas study characterized 316 primary 
HGSC specimens and detected TP53 mutations in 100% of 
specimens and BRCA1 and BRCA2 mutations (both somatic and 
germline) in 20%19,20. Most tumors were characterized by global 
genomic instability. More recent advances in DNA sequencing 
technology have identified additional mutations in ovarian cancer, 
including BARD1, BRIP1, CHEK2, NBN, PALB2, RAD50 family, 
and NF112,21–26. Given that these genes are involved in DNA repair, 
women with ovarian cancer, as well as their family members, are 
at risk of developing other cancers and thus should be referred for 
genetic counseling and testing27.
In ovarian cancer, as in other cancers, resistance to chemotherapy 
is common. To identify genes conferring chemoresistance, Patch 
et al. analyzed whole genome sequences of 92 patients with HGSC 
to characterize mutations from three groups of tumors: those that 
were sensitive to platinum, those that initially responded but then 
developed resistance, and those that did not respond at all28. They 
found TP53 mutations in all samples but found only a few, low- 
frequency, actionable genetic alterations amongst the chemoresist-
ant patients. These included reversion of germline mutations in 
BRCA1 and BRCA2, mutations in the pro-apoptotic genes FOXO1 
and BCL2L11, and increased expression of ABCB1, which encodes 
a cellular drug efflux pump. More work is clearly needed to uncover 
mechanisms of chemoresistance and strategies to overcome it.
Mechanisms of metastasis
Ovarian cancers are extremely prone to metastasize, particularly to 
the omentum. Two routes have been proposed to explain how ovar-
ian cancer cells reach the omentum. First, they may travel through 
the bloodstream, as suggested by Sood et al.29. These authors vas-
cularly conjoined 15 pairs of mice, intraperitoneally injected tumor 
cells into “host” mice, and found that half of the conjoined “guest” 
mice developed omental or mesenteric metastases. Tumor cells 
also reached the guest mouse when the cancer cells were injected 
into host ovaries or vasculature. The authors further found that the 
metastatic cells significantly upregulated expression of epidermal 
growth factor receptor family genes, specifically ErbB3, and that 
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targeting ErbB3 with small interfering RNA significantly inhib-
ited omental tumor establishment and also the size and number of 
tumors29. A second theory is that ovarian cancer cells metastasize 
by shedding into the peritoneal space and then attaching to nearby 
structures, such as the omentum. Support for this model comes 
from Lengyel et al., who showed that omental adipocytes promote 
metastasis to the omentum by upregulating expression of fatty acid-
binding protein 4 (FABP4)30. FABP4 was strongly expressed at the 
adipocyte–cancer cell interface, and mice lacking FABP4 had a sig-
nificantly lower tumor burden than wild-type mice. Future work 
will hopefully reveal whether the hematogenous or the shedding 
route predominates in different ovarian cancer types so that thera-
pies can be developed to prevent it.
Tumor cells and the microenvironment
Mutations do not explain the full spectrum of tumor behaviors, 
which also depend on the tumor microenvironment, or stroma, 
a mixture of extracellular matrix, mesothelial cells, fibroblasts, 
endothelial cells, blood and lymph vessels, nerves, immune cells, 
and adipocytes31–33. Two hallmarks of cancer that depend on the 
tumor microenvironment are (1) stromal invasion and metasta-
sis and (2) angiogenesis. Because stromal components contribute 
to ovarian cancer metastasis, many investigators are developing 
in vitro methods to study interactions with the tumor cells and 
identify strategies to inhibit metastasis by targeting tumor/microen-
vironment interactions. These methods include three-dimensional 
matrices, cancer cell spheroids, and co-cultured mesothelium (the 
first layer of the omentum) with cancer cells34. In studies with 
spheroids, Davidowitz et al. found that tumor cell spheroids that 
upregulated their expression of epithelial-to-mesenchymal tran-
sition transcription factors (in particular, SNAI1, TWIST1, and 
ZEB1) were better able to clear the mesothelium (an essential step 
in metastasis) than cells that did not upregulate these factors35. Addi-
tionally, receptor tyrosine kinases such as AXL and DDR2 have 
been found to regulate tumor cell clearance of primary, patient-
derived mesothelial cells36,37. For angiogenesis, Sood et al. used a 
xenograft approach to model what happens when a patient stops 
taking an anti-angiogenic drug such as bevacizumab or pazopanib38. 
They found that mice with higher circulating platelet levels had 
greater tumor weight and markers of proliferation and decreased 
levels of apoptosis. Furthermore, this group demonstrated that 
tumor infiltration of platelets after withdrawal of anti-angiogenic 
agents may contribute to rebound tumor growth. Incorporating the 
tumor microenvironment in future work will continue to lead to a 
better understanding of ovarian carcinogenesis and metastasis.
Translational mouse models
Understanding disease pathogenesis necessitates models that mimic 
patient tumor behavior and interaction with the microenvironment. 
One approach is to develop genetically engineered mouse models 
(GEMMs), in which a mouse’s genome is modified to cause devel-
opment of a murine disease that mimics human disease, although 
such models have not clearly resolved the question about the origin 
of ovarian tumors. Some authors have created conditional GEMMs 
that point to the ovary as the origin39–42, whereas other evidence 
points to the fallopian tube43,44. The first ovarian cancer model based 
on transformation of the fallopian tube epithelium as the origin was 
derived by using the Müllerian-specific Ovgp1 promoter to drive 
expression of the SV40 large T-antigen and thus induce tumorigen-
esis in the fallopian tube45. More recently, Perets et al. generated 
a model in which they specifically deleted BRCA, TP53, or PTEN 
in the fallopian tube and found that these mice developed HGSCs, 
tubal transformation, and peritoneal spread46. Interestingly, when the 
researchers removed the ovaries, the mice developed STIC lesions 
and tubal transformation but not peritoneal metastasis, suggesting 
that the ovary plays a crucial role in the spread of IP disease46.
A second type of in vivo model is cell line-based xenografts, in 
which cancer cell lines are implanted into an immunocompromised 
mouse or, even better, into a mouse that is syngeneic with the cell 
line, such as the spontaneous ovarian cancer line ID8 derived from 
a C57Bl/6 mouse. Although this ID8 line has been used for many 
years, Walton et al. recently sequenced it and found that it was wild-
type for TP53 and BRCA1 and BRCA247, whereas 98% of human 
ovarian cancers contain a TP53 mutation. Introducing a TP53 or 
BRCA2 mutation (or both) caused these cells to develop tumors and 
surrounding microenvironment phenotype that more closely mim-
icked human ovarian cancers in terms of speed and distribution of 
metastases.
A third approach to translational mouse models is the use of patient-
derived xenografts (PDXs), which are created by implanting patient 
specimens into mice to study tumor behaviors. Several groups have 
developed ovarian cancer PDXs48–51 that respond to treatment in a 
manner similar to that of the patients’ tumors. For example, Landen 
et al. created subcutaneous PDX models of ovarian cancer and 
assessed gene expression in both the patients’ tumors and the PDXs 
after they developed chemoresistance50. The authors identified 
five affected signaling pathways (protein kinase A, GNRH, 
sphingosine-1-phosphate, α-adrenergic, and cholecystokinin/ 
gastrin-mediated) that were shared between the patients’ tumors 
and the corresponding PDXs. Models such as these provide usa-
ble platforms to study tumor and stromal elements contributing to 
tumorigenesis and the effects of various therapies.
Diagnosis and prevention
Screening in low-risk patients
No validated screening tests exist for early detection of ovarian can-
cer in low-risk women. Although some tests have been developed 
to assess known adnexal masses, the US Food and Drug Adminis-
tration (FDA) recently issued a statement recommending against 
using any of these as screening tools in the general population52. 
Similarly, the US Preventative Services Task Force gives screen-
ing asymptomatic women a D grade, meaning that there is moder-
ate to high certainty that the service has no net benefit or that the 
harms of such a service may outweigh any benefit53. For example, 
the FDA has approved the OVA1 test for women who have already 
been found to have an ovarian tumor, but it is not a screening test. 
The largest randomized controlled trials (RCTs) have assessed a 
combination of serum markers and ultrasound imaging, but these 
tests have proved to have inadequate sensitivity or specificity, have 
resulted in high rates of unnecessary interventions (65–97% of 
Page 4 of 12
F1000Research 2017, 6(F1000 Faculty Rev):84 Last updated: 27 JAN 2017
screen-positive women who underwent surgical intervention did 
not actually have cancer), or were unable to reduce ovarian cancer-
related mortality54–56. This is an important area for future research.
Special considerations in high-risk patients
Patients who carry particular inherited mutations warrant 
screening57 because the lifetime risk of ovarian cancer in the gen-
eral populations is 1.3% but can be as high as 40–60% in BRCA1 
and BRCA2 mutation carriers58–62 and 10–15% in Lynch syndrome 
mutation carriers5,63. As additional high-risk mutations are identi-
fied in multi-gene panels, we may be able to identify more high-risk 
patients.
Advances in high-risk prevention
Women who carry high-risk mutations are recommended to undergo 
risk-reducing bilateral salpingo-oophorectomy (RRSO) (removal 
of the fallopian tubes and ovaries) by age 35 to 40 for BRCA1 and 
40 to 45 for BRCA227,64. A national trial (GOG-0199) comparing 
RRSO with longitudinal screening will hopefully clarify both the 
necessary screening frequency and the non-oncological outcomes 
of ovary removal, such as heart disease and osteoporosis65, in high-
risk patients.
Because removal of the ovary can cause earlier onset of menopause, 
increased risks to cardiac and bone health, and other impairments 
to quality of life, studies are underway to determine the efficacy 
of removing the fallopian tubes (salpingectomy) immediately 
but delaying ovary removal (oophorectomy) for several years. 
Harmsen et al. used previous data of cumulative ovarian cancer 
risk for BRCA mutation carriers to mathematically compare the 
risks of immediate RRSO with those of immediate salpingec-
tomy with delayed oophorectomy66. The authors concluded that a 
five-year delay in oophorectomy would increase the rates of ovar-
ian cancer by 4.1% and 1.8% for those with mutations in BRCA1 
and BRCA2, respectively, even if the initial salpingectomy afforded 
no reduction of risk. Kwon et al. created a model to compare costs 
and benefits of RRSO at age 40 versus salpingectomy at age 40 
with oophorectomy at age 50 in BRCA1 and BRCA2 mutation 
carriers67. Although RRSO at age 40 was more effective in both 
cost and overall life expectancy, salpingectomy plus delayed 
oophorectomy resulted in higher quality-adjusted life expectancy.
Hormonal agents in high-risk patients
An important issue to consider is that RRSO is associated with 
menopausal symptoms such as sexual dysfunction, hypoactive 
sexual desire, and less frequent sexual encounters68–70. Thus, RRSO 
patients may receive hormone therapy, which Kwon et al. assumed 
would not be the case in the cost–benefit analysis discussed above. 
Thus far, no RCTs have been conducted to address this issue. One 
recent systematic literature review71 assessed the safety of hormone 
therapy in RRSO patients with BRCA mutations and found that 
women were likely to benefit symptomatically from hormone ther-
apy and did not have an increased risk of breast cancer, but there 
was insufficient evidence regarding ovarian cancer risk. Additional 
studies are needed to assess ovarian cancer risk and outcomes of 
risk-reducing procedures in patients carrying Lynch syndrome 
mutations.
Optimizing chemotherapy and developing innovative 
therapeutics
Optimizing chemotherapy
Chemotherapy has long been incorporated into the care of patients 
with HGSC; however, the how, when, and which have become less 
clear as more options are available for front-line treatment. In the 
first decade of the 21st century, two randomized trials (GOG 114 
and GOG 172) demonstrated that, after optimal tumor resection, 
women who received combination intravenous/IP (IV/IP) cisplatin 
and paclitaxel-containing chemotherapy had significantly better 
progression-free survival (PFS) (5.7 and 5.5 months) and overall 
survival (OS) (11.0 and 15.9 months) than those who received IV-
only regimens72,73. This survival advantage in the IP groups was seen 
even though the IP patients had significant hematologic, metabolic, 
neurologic, and gastrointestinal toxicities, and only 71% and 42% 
of each study’s IP participants completed all six cycles72,73. Because 
of these toxicities and missed cycles, over time providers modified 
the regimen and instead gave patients alternate therapy schedules, 
reduced dosages, and substituted drugs, as described by Wright 
et al.74. Another option for chemotherapy regimen was provided 
by a Japanese study showing that a lower but more frequent dose 
of paclitaxel (“dose-dense paclitaxel”) led to improved PFS and 
OS75. Additionally, the GOG-0218 trial demonstrated that the 
use of bevacizumab in the front-line and maintenance setting 
improved PFS by 3.8 months when compared with conventional 
every-3-weeks carboplatin and paclitaxel76.
Recently, the GOG-0252 trial was undertaken in an attempt to 
identify the best front-line regimen given the improved sur-
vival data seen with IP chemotherapy and dose-dense paclitaxel 
when compared with conventional every-3-weeks carboplatin 
and paclitaxel. This study had three arms, each of which included 
bevacizumab therapy in addition to (1) IV dose-dense paclitaxel 
and IV carboplatin, (2) IV dose-dense paclitaxel and IP carbopla-
tin, and (3) IV/IP paclitaxel with IP cisplatin at a reduced dose. 
PFS and toxicities were found to be similar amongst all three 
treatment regimens, although some participant cross-over between 
arms may have clouded results77. We are awaiting OS data as 
they mature to help determine whether there is a superior front-line 
regimen.
Not only has the best route been intensely debated but the 
optimal timing of therapy has been and is currently being stud-
ied. Chemotherapy is usually given either (1) only after primary 
debulking surgery (PDS) or (2) as both neoadjuvant chemo-
therapy (NACT) before and after interval debulking surgery (IDS). 
The goal of any cytoreductive surgery is to maximally reduce 
the disease, as doing so is well known to improve patient 
outcomes78–80. However, recent trials have tried to determine 
whether patients receiving NACT and post-IDS chemotherapy have 
better outcomes than those receiving only chemotherapy after PDS. 
Initially, several large RCTs found that the NACT/IDS regimen 
was non-inferior to the PDS regimen in terms of PFS and OS and 
overall morbidities. However, the OS of the groups was lower than 
expected, suggesting that the included patients somehow differed 
from the larger collective population of patients with HGSC81–84. 
Subsequent reports noted that recurrences after NACT/IDS 
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regimens were more likely to be platinum-resistant and were less 
responsive to second-line therapies than those that occurred after 
PDS regimens, and some studies even demonstrated better PFS and 
OS in those who received regimens after PDS85–90 when compared 
with those after NACT/IDS. There is likely a contributing biologi-
cal factor, yet to be determined, for tumors that present as unre-
sectable versus those that can be resected to no residual disease 
with PDS. Controversy with NACT/IDS exists given the possibil-
ity of a compromised responsiveness to additional lines of therapy 
including platinum-containing agents and possibly a risk of higher 
recurrence rates. Nonetheless, a NACT/IDS regimen may be the 
best option for patients with particular comorbidities, histological 
subtypes, or other clinical situations making them unable to tolerate 
an aggressive, up-front surgical procedure.
Developing innovative therapeutics
Traditionally, ovarian cancer has been treated with cytotoxic agent 
regimens chosen on the basis of cancer stage, and most patients 
have eventually developed chemotherapy resistance, leading to 
overwhelming disease burden and death. Researchers are working 
to find innovative methods to restore chemosensitivity and develop 
adjuvants to improve the function of cytotoxics to decrease required 
doses and improve toxicity profiles. In addition, researchers are 
investigating novel agents targeting specific tumor mutations. We 
highlight some promising findings below.
Preclinical development
Nanoparticle technology is a promising method by which to intro-
duce therapeutics and minimize off-target effects. In one study, 
Landen et al. treated a mouse model of ovarian cancer with nano-
liposomal particles containing small interfering RNAs targeting can-
cer stem cells in combination with either docetaxel or cisplatin91. 
This regimen reduced tumor growth more than chemotherapy 
alone. In another study, researchers used nanoliposomal particles to 
target a cell membrane transporter involved in cellular extrusion of 
chemotherapeutic drugs. This approach was able to restore paclit-
axel sensitivity both in vitro and in vivo92. A nanoparticle derived of 
a naturally occurring alcohol was recently demonstrated to improve 
apoptosis and inhibit tumor growth when combined with paclitaxel 
in vitro and in vivo93. Other promising therapeutics target various 
parts of the surrounding tumor stroma. For example, Wang et al. 
found that the peptide prosaposin could inhibit metastasis in a 
platinum-resistant PDX model by stimulating the release of 
anti-tumorigenic protein thrombospondin-1 from surrounding 
monocytes94.
SHIVA and MATCH clinical trials
Given the success of targeted therapies based on tumor mutational 
status in lung cancer and melanoma, this approach is being investi-
gated in other solid cancers, including ovarian cancer. The SHIVA 
(A Randomized Phase II Trial Comparing Therapy Based on Tumor 
Molecular Profiling Versus Conventional Therapy in Patients With 
Refractory Cancer) trial in France was a multicenter, phase II RCT 
of 195 histology-agnostic, heavily pretreated patients (of whom 29 
had ovarian cancer). Patients were randomly assigned to either the 
physician’s choice of drug or a molecularly targeted agent that was 
matched to the patient tumor molecular profile but was not approved 
for that tumor type. Although the study reported no difference in 
PFS between the two groups95, the study was powered to detect 
only a 15–30% improvement and may have missed smaller effects. 
In the ongoing National Cancer Institute-initiated Molecular Analy-
sis for Therapy Choice (MATCH) trial, all recurrent, solid tumors 
undergo targeted exome sequencing to identify mutations, and the 
patients are treated with a matched targeted therapy until disease 
progression96. This ongoing trial includes patients with ovarian 
cancer and will provide useful information about the value of this 
genomics-based approach to treatment.
FDA-approved agents
Only two targeted agents are currently FDA-approved for use 
in ovarian cancer. Olaparib, a poly-ribose polymerase (PARP) 
inhibitor, was approved in 2014 for use in patients with BRCA1/2 
mutations who have been treated with three or more previous 
lines of chemotherapy. Bevacizumab, a vascular endothelial 
growth factor (VEGF) anti-angiogenic, also received FDA 
approval in 2014 for use in recurrent, platinum-resistant patients in 
combination with paclitaxel, topotecan, or pegylated liposomal 
doxorubicin. A number of other targeted therapeutics, includ-
ing additional PARP inhibitors, anti-angiogenics, tyrosine kinase 
inhibitors, and immunotherapeutics, are currently being investi-
gated (Table 1).
Immunotherapy
The possible effectiveness of immunotherapeutic approaches in 
ovarian cancer was suggested by a 2003 study reporting that ovar-
ian cancer patients whose tumors contained CD3+ T cells expe-
rienced a higher five-year OS rate than those whose tumors did 
not contain those cells (38% versus 4.5%). In another approach, 
patients are “immunized” with tumor antigens. Although positive 
antibody responses have been reported, no vaccination approach 
has yet improved any clinically relevant outcomes in ovarian 
cancer97–99.
In several cancer types, investigators are attempting to block pro-
grammed death 1 (PD-1), a protein that protects tumor cells from 
immune system attack, but so far little work has been done in this 
area for ovarian cancer. In a single phase II study, the anti-PD-1 
antibody nivolumab produced an overall response rate of 15% (3 
out of 20) and a median PFS of 3.5 months. Similarly, in a pre-
liminary report of a phase IB study using the anti-PD-1 antibody 
pembrolizumab in patients with ovarian cancer that expressed the 
PD-1 ligand, the overall response rate was 3 out of 20100. Although 
the overall response rate was low, two patients had complete and 
durable remissions of up to one year.
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Table 1. Recent and ongoing clinical trials using targeted therapeutics for high-grade serous Müllerian 
adenocarcinomas.
Class Agent Target(s) Trial group/name, phase Progression-free 
survival and overall 
survival, months
Anti-angiogenics
Bevacizumaba VEGF ICON-7, phase III101 
GOG-0218, phase III76 
 
 
OCEANS, phase III102 
AURELIAa, phase III103




PFS 12.4/OS 33.3 
PFS 6.7/OS 16.6
Cabozantinib c-met, VEGFR2, RET, 
AXL
NRG-GY001, phase II104 -
Cediranib VEGFR2/3/4, c-kit Multicenter, phase II105 
NRG-GY004, phase III106 
NRG-GY005, phase II/III107





GOG-0186I, phase II108 PFS 7.3/OS 24.6
Trebananib/AMG386 Angiopoietin-1/2 TRINOVA1, phase III109,110 
TRINOVA2-3, phase III111,112
PFS 7.2/OS 19.3 
-
PARP inhibitors
Olapariba PARP Multicentera, phase II113 
Multicenter, phase II114,115 
NRG-GY004, phase III106 
NRG-GY005, phase II/III107
PFS 7.0/OS 16.6 
PFS 8.4/OS 29.8b 
- 
-
Niraparib PARP ENGOT-OV16/Nova Trial 
(multi-arm), phase III116 
QUADRA, phase II117
PFS 21+12.9+9.3 /OS 
not yet mature 
-
Veliparib PARP GOG-3005, phase III118 -
Rucaparib PARP ARIEL2-4, phase II/III119–121 -
Pazopanib PARP GOG-0186J, phase II122 -
Cabozantinib PARP GOG-0186K, phase II123 -
Immunologics
EGEN-001 IL-12 GOG-0170Q, phase II124 PFS 2.9/OS 9.2
Nivolumab PD-1 NRG-GY003, phase II125 -
Ruxolitinib JAK1, JAK2 NRG-GY007, phase I/II126 -
VTX-2337 TLR8 GOG-3003, phase II127 -
Pathway inhibitors
Temsirolimus MTOR GOG-0268, phase II128 PFS 3.2/OS 11.6
aUS Food and Drug Administration approval gained. bOverall survival (OS) may be underestimated; OS = 31.9 months when 
crossover poly-ribose polymerase (PARP) exposure post-trial is included129. Italics indicate trial in progress or awaiting 
data analysis. GOG, Gynecologic Oncology Group; IL-12, interleukin-12; JAK, Janus Kinase; MTOR, mammalian target of 
rapamycin; NRG, NSABP/RTOG/GOG Collaborative Group; PD-1, programmed death 1; PFS, progression-free survival; TLR8, 
Toll-like receptor 8; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2.
Conclusions
Since the incorporation of taxane-containing chemotherapy 
into standard treatment, the survival of patients with ovarian can-
cer has improved only slightly. However, the current research 
highlighted here gives us hope that survival rates will continue 
to increase as there is further development of in vivo mouse 
models, in vitro tumor microenvironment models, identifica-
tion of pathways activated in chemoresistance, immunotherapy, 
optimization of chemotherapy regimens, and development of tar-
geted agents. In addition, cost models are needed to determine the 
feasibility and sustainability of widespread usage of newly devel-
oped approaches.
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